Insignificant prostate cancer on prostatectomy and cystoprostatectomy: Variation on a theme 'low-volume/ low-grade' prostate cancer?: Review article

BJU International

Volumn 106, Issue 3, 2010, Pages 304-315

  Trpkov, Kiril ^a   Yilmaz, Asli ^a   Bismar, Tarek A ^a   Montironi, Rodolfo ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Cystoprostatectomy; Incidental prostate cancer; Indolent prostate cancer; Insignificant prostate cancer; Minimal prostate cancer; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT; CRYOTHERAPY; CYSTECTOMY; GLEASON SCORE; HUMAN; NOMOGRAM; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; TUMOR GROWTH; TUMOR VOLUME;

AGED; BIOPSY, NEEDLE; CYSTECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 77955739401     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09499.x     Document Type: Review

References (108)

1. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004 172 : 1297 1301
2. Makarov DV, Trock BJ, Humphreys EB et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007 69 : 1095 1101
3. Babaian RJ, Toi A, Kamoi K et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000 163 : 152 7
4. Brossner C, Bayer G, Madersbacher S, Kuber W, Klingler C, Pycha A. Twelve prostate biopsies detect significant cancer volumes (>0.5 mL). BJU Int 2000 85 : 705 707
5. Master VA, Chi T, Simko JP, Weinberg V, Carroll PR. The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol 2005 174 : 1789 1793
6. Guzzo TJ, Vira M, Hwang WT et al. Impact of multiple biopsy cores on predicting final tumor volume in prostate cancer detected by a single microscopic focus of cancer on biopsy. Urology 2005 66 : 361 365
7. Ochiai A, Troncoso P, Chen ME, Lloreta J, Babaian RJ. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. J Urol 2005 174 : 2164 2168
8. Chan TY, Chan DY, Stutzman KL, Epstein JI. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol 2001 166 : 2181 2184
9. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 94 : 981 990
10. Graif T, Loeb S, Roehl KA et al. Under diagnosis and over diagnosis of prostate cancer. J Urol 2007 178 : 88 92
11. Adolfsson J. [Editorial Comment]. J Urol 2005 174 : 2168
12. Klotz L. What is the best approach for screen-detected low volume cancers? - The case for observation. Urol Oncol 2008 26 : 495 499
13. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993 71 (Suppl 933 938
14. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 271 : 368 374
15. Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998 160 : 2407 2411
16. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996 275 : 288 294
17. Sengupta S, Blute ML, Bagniewski SM et al. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int 2008 101 : 170 174
18. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003 170 : 1792 1797
19. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007 177 : 107 112
20. Klein EA. What is 'insignificant' prostate carcinoma? Cancer 2004 101 : 1923 5
21. Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 2003 170 : 459 463
22. Humphrey PA, Vollmer RT. Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 1997 10 : 326 333
23. Mazzucchelli R, Barbisan F, Santinelli A et al. Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer. Urology 2009 74 : 385 390
24. Winfield HN, Reddy PK, Lange PH. Coexisting adenocarcinoma of prostate in patients undergoing cystoprostatectomy for bladder cancer. Urology 1987 30 : 100 101
25. Pritchett TR, Moreno J, Warner NE et al. Unsuspected prostatic adenocarcinoma in patients who have undergone radical cystoprostatectomy for transitional cell carcinoma of the bladder. J Urol 1988 139 : 1214 1216
26. Montie JE, Wood DP Jr., Pontes JE, Boyett JM, Levin HS. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989 63 : 381 385
27. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 1989 141 : 1091 1094
28. Abbas F, Hochberg D, Civantos F, Soloway M. Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Eur Urol 1996 30 : 322 326
29. Moutzouris G, Barbatis C, Plastiras D et al. Incidence and histological findings of unsuspected prostatic adenocarcinoma in radical cystoprostatectomy for transitional cell carcinoma of the bladder. Scand J Urol Nephrol 1999 33 : 27 30
30. Aydin O, Cosar EF, Varinli S, Bugdayci R, Tansug Z. Prostatic intraepithelial neoplasia in prostate specimens: frequency, significance and relationship to the sampling of the specimen (a retrospective study of 121 cases). Int Urol Nephrol 1999 31 : 687 697
31. Yang CR, Ou YC, Ho HC et al. Unsuspected prostate carcinoma and prostatic intraepithelial neoplasm in Taiwanese patients undergoing cystoprostatectomy. Mol Urol 1999 3 : 33 9
32. Conrad S, Hautmann SH, Henke RP et al. Detection and characterization of early prostate cancer by six systematic biopsies and fine needle aspiration cytology in prostates from bladder cancer patients. Eur Urol 2001 39 (Suppl. 4 25 9
33. Prange W, Erbersdobler A, Hammerer P et al. High-grade prostatic intraepithelial neoplasia in cystoprostatectomy specimens. Eur Urol 2001 39 (Suppl. 4 30 1
34. Cindolo L, Benincasa G, Autorino R et al. Prevalence of silent prostatic adenocarcinoma in 165 patients undergone cystoprostatectomy: a retrospective study. Oncol Report 2001 8 : 269 271
35. Ward JF, Bartsch G, Sebo TJ, Pinggera GM, Blute ML, Zincke H. Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? Urol Oncol 2004 22 : 40 7
36. Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA Jr., Shappell SB. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol 2004 171 : 646 651
37. Kouriefs C, Fazili T, Masood S, Naseem MS, Mufti GR. Incidentally detected prostate cancer in cystoprostatectomy specimens. Urol Int 2005 75 : 213 6
38. Delongchamps NB, Mao K, Theng H, Zerbib M, Debre B, Peyromaure M. Outcome of patients with fortuitous prostate cancer after radical cystoprostatectomy for bladder cancer. Eur Urol 2005 48 : 946 950 (Pubitemid 41641641)
39. Ruffion A, Manel A, Massoud W et al. Preservation of prostate during radical cystectomy: evaluation of prevalence of prostate cancer associated with bladder cancer. Urology 2005 65 : 703 707
40. Lee SH, Chang PL, Chen SM et al. Synchronous primary carcinomas of the bladder and prostate. Asian J Androl 2006 8 : 357 359
41. Rocco B, de Cobelli O, Leon ME et al. Sensitivity and detection rate of a 12-core trans-perineal prostate biopsy: preliminary report. Eur Urol 2006 49 : 827 833
42. Abdelhady M, Abusamra A, Pautler SE, Chin JL, Izawa JI. Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens. BJU Int 2007 99 : 326 329
43. Winkler MH, Livni N, Mannion EM, Hrouda D, Christmas T. Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. BJU Int 2007 99 : 554 558
44. Hosseini SY, Danesh AK, Parvin M et al. Incidental prostatic adenocarcinoma in patients with PSA less than 4 ng/mL undergoing radical cystoprostatectomy for bladder cancer in Iranian men. Int Braz J Urol 2007 33 : 167 173
45. Weizer AZ, Shah RB, Lee CT et al. Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol 2007 25 : 460 464
46. Esgueva R, Lorente J, Mojal S et al. Incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens: the impact of embedding protocols. Mod Pathol 2008 21 (Suppl. 1) 155A
47. Abstract M, Abdel-Rahim M, Abol-Enein H, Ghoneim MA. Concomitant pathology in the prostate in cystoprostatectomy specimens: a prospective study and review. BJU Int 2008 102 : 1544 1550
48. Mazzucchelli R, Barbisan F, Scarpelli M et al. Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant? Am J Clin Pathol 2009 131 : 279 283
49. Damiano R, Di Lorenzo G, Cantiello F et al. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol 2007 52 : 648 657
50. Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992 148 : 829 832
51. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994 152 : 1714 1720
52. Montironi R, Mazzucchelli R, Santinelli A, Scarpelli M, Beltran AL, Bostwick DG. Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens. Hum Pathol 2005 36 : 646 654
53. Montironi R, Mazzucchelli R, Barbisan F et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 2006 37 : 1137 1144
54. Santinelli A, Mazzucchelli R, Barbisan F et al. alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer. Am J Clin Pathol 2007 128 : 657 666
55. Barbisan F, Mazzucchelli R, Santinelli A et al. Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. Eur Urol 2009 56 : 105 112
56. Sheldon CA, Williams RD, Fraley EE. Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. J Urol 1980 124 : 626 631
57. Liskow AS, Neugut AI, Benson M, Olsson CA, Birkhoff J, Chang CH. Multiple primary neoplasms in association with prostate cancer in black and white patients. Cancer 1987 59 : 380 384
58. Barbisan F, Mazzucchelli R, Scarpelli M et al. Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer? BJU Int 2009 103 : 1058 1063
59. Autorino R, Di Lorenzo G, Giannarini G et al. Looking at the prostates of patients with bladder cancer: a thoughtful exercise. BJU Int 2009 104 : 160 162
60. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996 156 : 1059 1063
61. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 1994 44 : 862 868
62. Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology 1995 45 : 75 80
63. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995 153 : 1543 1548
64. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol 1997 157 : 244 250
65. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 1997 157 : 2206 2209
66. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001 166 : 104 110
67. Augustin H, Hammerer PG, Graefen M et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 2003 43 : 455 460
68. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004 64 : 544 50
69. Miyake H, Sakai I, Harada K, Hara I, Eto H. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease. Int J Urol 2005 12 : 270 274
70. Chun FK, Haese A, Ahyai SA et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008 113 : 701 709
71. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002 167 : 528 534
72. Thorson P, Vollmer RT, Arcangeli C, Keetch DW, Humphrey PA. Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol 1998 11 : 543 551
73. Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. Am J Clin Pathol 2000 114 : 896 909
74. van der Kwast TH, Wolters W, Evans A, Roobol M. Single prostatic cancer foci on prostate biopsy. Eur Urol Suppl 2008 7 : 549 556
75. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003 170 : 370 372
76. Trpkov K, Tsui J, Yilmaz A. Minimal prostate cancer with ten-core prostate biopsy: clinical and pathological findings and correlation with radical prostatectomy. Mod Pathol 2003 16 (Suppl. 1) 174A
77. Abstract A, Trpkov K, Yilmaz A, Donnelly B, Babaian RJ. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance. J Urol 2007 177 : 907 910
78. Ravery V, Szabo J, Toublanc M et al. A single positive prostate biopsy in six does not predict a low-volume prostate tumour. Br J Urol 1996 77 : 724 728
79. Wang X, Brannigan RE, Rademaker AW, McVary KT, Oyasu R. One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. J Urol 1997 158 : 1431 1435 (Pubitemid 27391213)
80. Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD. The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer 2008 112 : 971 981 (Pubitemid 351304580)
81. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006 24 : 46 50 (Pubitemid 43097357)
82. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004 101 : 2001 2005
83. Jeldres C, Suardi N, Walz J et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008 54 : 1306 1313
84. Lee SE, Kim DS, Lee WK et al. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean Men. BJU Int 2010 105 : 1526 1530
85. Lee MC, Dong F, Stephenson AJ, Jones JS, Magi-Galluzzi C, Klein EA. The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 2009 Epub ahead of print]. DOI:10.1016/j.eururo.2009.10.025
86. Stephenson AJ, Kattan MW, Eastham JA et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009 27 : 4300 4305
87. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004 172 : 508 511
88. Merrill MM, Lane BR, Reuther AM, Zhou M, Magi-Galluzzi C, Klein EA. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer. Urology 2007 70 : 294 298
89. Nakanishi H, Wang X, Ochiai A et al. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer 2007 110 : 2441 2447
90. Chun FK, Briganti A, Jeldres C et al. Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer 2007 43 : 536 543
91. Osunkoya AO, Carter HB, Epstein JI. A clinicopathologic study of preoperative and postoperative findings with minute Gleason 3+3=6 cancer at radical prostatectomy. Urology 2008 72 : 638 40
92. Trpkov K, Zhang J, Yilmaz A. Prostatectomy and preoperative findings in patients with prostate cancer (PCA) involving ≤1% gland volume. Virchows Arch 2009 455 (Suppl. 1 S67
93. Humphrey PA. Complete histologic serial sectioning of a prostate gland with adenocarcinoma. Am J Surg Pathol 1993 17 : 468 472
94. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005 310 : 644 648
95. Perner S, Mosquera JM, Demichelis F et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007 31 : 882 888
96. Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther 2009 8 : 125 130
97. Demichelis F, Fall K, Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007 26 : 4596 4599
98. Nam RK, Sugar L, Wang Z et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007 6 : 40 5
99. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008 14 : 3395 3400
100. Albadine R, Latour M, Toubaji A et al. TMPRSS2:ERG: gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 2009 22 : 1415 1422
101. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008 179 : 1804 1809
102. Leman ES, Cannon GW, Trock BJ et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007 69 : 714 720
103. Yang SY, Adelstein J, Kassis AI. Putative molecular signatures for the imaging of prostate cancer. Expert Rev Mol Diagn 2010 10 : 65 74
104. Donnelly BJ, Saliken JC, Brasher PM et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010 116 : 323 330
105. Katz AE, Kacker R. Focal treatment for low-risk prostate cancer. BJU Int 2008 102 : 158 159
106. Ward JF, Nakanishi H, Pisters L, Babaian RJ, Troncoso P. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 2009 104 : 490 497
107. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996 30 : 138 144
108. Yin M, Bastacky S, Chandran U, Becich MJ, Dhir R. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol 2008 179 : 892 895